These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32705748)

  • 1. COVID-19 in Rheumatic Diseases: A Research Agenda.
    Yazdany J
    Arthritis Rheumatol; 2020 Oct; 72(10):1596-1599. PubMed ID: 32705748
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.
    Galarza-Delgado DÁ; Serna-Peña G; Compeán-Villegas JE; Cardenas-de la Garza JA; Pineda-Sic RA; Colunga-Pedraza IJ; Vega-Morales D; Pérez-Barbosa L; Skinner-Taylor CM; Flores-Alvarado DE
    Clin Rheumatol; 2021 Mar; 40(3):1197-1199. PubMed ID: 33231774
    [No Abstract]   [Full Text] [Related]  

  • 3. Rheumatic disease and COVID-19: epidemiology and outcomes.
    Hyrich KL; Machado PM
    Nat Rev Rheumatol; 2021 Feb; 17(2):71-72. PubMed ID: 33339986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.
    Sagnelli C; Gentile V; Tirri R; Macera M; Cappabianca S; Ciccia F; Coppola N;
    J Infect; 2020 Dec; 81(6):979-997. PubMed ID: 32474034
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques
    D'Silva KM; Serling-Boyd N; Wallwork R; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2022 Aug; 81(8):e135. PubMed ID: 32660976
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.
    Celik S; Kutu ME; Bal C; Karadeniz B; Atagunduz P; Soy M
    Clin Exp Rheumatol; 2023 Mar; 41(3):758-759. PubMed ID: 36226619
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
    Erre GL; Ferraccioli ES; Piga M; Mangoni A; Passiu G; Gremese E; Ferraccioli G
    Ann Rheum Dis; 2021 Mar; 80(3):e29. PubMed ID: 32424028
    [No Abstract]   [Full Text] [Related]  

  • 8. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
    D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2021 Jun; 80(6):817-819. PubMed ID: 33436385
    [No Abstract]   [Full Text] [Related]  

  • 9. Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Aydin SZ; Hepworth E; Tugwell P
    Ann Rheum Dis; 2023 Mar; 82(3):e69. PubMed ID: 33355117
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 11. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco
    Giollo A; Bertoldo E; Adami G; Cybulski AJ; Fassio A; Orsolini G; Idolazzi L; Gatti D; Viapiana O; Rossini M
    Ann Rheum Dis; 2022 Nov; 81(11):e222. PubMed ID: 32895237
    [No Abstract]   [Full Text] [Related]  

  • 12. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
    Sozeri B; Ulu K; Kaya-Akça U; Haslak F; Pac-Kisaarslan A; Otar-Yener G; Baba O; Altug-Gucenmez O; Sahin N; Bağlan E; Sönmez HE; Cakmak F; Ozturk K; Gezgin-Yıldırım D; Şener S; Barut K; Batu ED; Yıldız M; Basaran O; Adrovic A; Sahin S; Ozdel S; Bilginer Y; Poyrazoglu MH; Demir F; Yuksel S; Kalyoncu M; Kasapcopur O; Ozen S; Aktay-Ayaz N
    Rheumatol Int; 2022 Mar; 42(3):469-475. PubMed ID: 34570263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Individual and interdisciplinary treatment of rheumatic diseases in pregnancy].
    Bolz M
    Dtsch Med Wochenschr; 2008 Nov; 133(46):2415. PubMed ID: 18988135
    [No Abstract]   [Full Text] [Related]  

  • 14. Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'.
    Rosenbaum JT; Weisman MH; Shafer C; Aslanyan E; Howard RA; Ogle K; Hamilton H; Reveille JD; Winthrop KL; Choi D
    Ann Rheum Dis; 2023 Jun; 82(6):e138. PubMed ID: 33985940
    [No Abstract]   [Full Text] [Related]  

  • 15. Should we switch from analgesics to the concept of "Pain Modifying Analgesic Drugs (PMADs)" in osteoarthritis and rheumatic chronic pain conditions?
    Perrot S
    Pain; 2009 Dec; 146(3):229-230. PubMed ID: 19695777
    [No Abstract]   [Full Text] [Related]  

  • 16. Bibliography. Current world literature. Clinical therapeutics.
    Curr Opin Rheumatol; 2008 May; 20(3):360-6. PubMed ID: 18388531
    [No Abstract]   [Full Text] [Related]  

  • 17. Rheumatic disease management in the Campania region of Italy during the COVID-19 pandemic.
    Masini F; Gjeloshi K; Ferrara R; Pinotti E; Cuomo G
    Rheumatol Int; 2020 Sep; 40(9):1537-1538. PubMed ID: 32666135
    [No Abstract]   [Full Text] [Related]  

  • 18. Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global rheumatology alliance registry.
    Int J Rheum Dis; 2021 Dec; 24(12):1547. PubMed ID: 34854242
    [No Abstract]   [Full Text] [Related]  

  • 19. The eye in rheumatology.
    Odufuwa TO; Lightman S
    Hosp Med; 2003 Jan; 64(1):46-8. PubMed ID: 12572337
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
    Friedman MA; Curtis JR; Winthrop KL
    Ann Rheum Dis; 2021 Oct; 80(10):1255-1265. PubMed ID: 34493491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.